Neutral
The FDA has approved Viridian Therapeutics' drug Lumvoa for thyroid eye disease, positioning it as a strong competitor to Amgen's Tepezza. Analysts be...
Bearish
The New England Journal of Medicine has retracted a 2021 article on Amgen's rare-disease drug, Tavneos, following an FDA investigation. The retraction...
Bearish
The FDA has announced a recall of nearly one million bottles of Amgen Inc.'s Corlanor and Sensipar medications. Corlanor is being recalled due to the ...
Neutral
The FDA has approved Viridian Therapeutics' Lumvoa for treating both chronic and active phases of thyroid eye disease (TED), making it the second appr...
Neutral
Nicholas Wealth LLC. acquired a new position in Amgen Inc. (NASDAQ:AMGN – Free Report) during the 1st quarter, according to the company in its most re...
Neutral
This article presents the enterprise value to EBIT forward for Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs (BCBA:AMGDB). The content appears to...
The European Medicines Agency has recommended the revocation of Amgen's Tavneos marketing authorization, citing concerns over data integrity from its ...
A recent patent victory by Harbour BioMed against Amgen highlighted legal risks, yet Amgen's stock still appears 2.1% undervalued based on its advance...
Neutral
Amgen, known for its innovative biologic medicines, has also become a leader in biosimilars, a business segment that significantly contributes to its ...
A new real-world study, presented at the ARVO Annual Meeting, analyzed data from over 34,000 patients to reveal that Thyroid Eye Disease (TED) progres...
Neutral
Rockefeller Capital Management L.P. raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 27.5% during the fourth quarter, according to its...
Neutral
This article compares Amgen and NovoCure as potential healthcare stock investments for 2026, highlighting their different business models and risk pro...
Neutral
Amgen's stock is often viewed through the lens of patent expirations, but the company's "key growth drivers," a portfolio of newer drugs and biosimila...
Neutral
Integrity Wealth Advisors Inc. decreased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 58.8% in the 4th quarter, according to the company ...
Neutral
Amgen reported strong Q1 2026 results, with key growth drivers increasing sales by 24% year-over-year, absorbing losses from expiring patents. The com...
Neutral
Mizuho analyst Salim Syed maintained a Neutral rating on Amgen (AMGN) but raised its price target from $295 to $303 on June 16, 2026. Amgen is current...
Neutral
Amgen Inc. has terminated its lobbying relationship with Washington Advocacy Group, a move driven by the evolving landscape of healthcare regulations ...
Neutral
Rakuten Investment Management Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 266.9% in the fourth quarter, according to ...
Bearish
A U.S. jury has found Amgen Inc. liable for patent infringement against Harbour BioMed, awarding the drug developer $20.2 million in damages. The verd...
Neutral
Van ECK Associates Corp significantly reduced its stake in Amgen Inc. by 39.8% in Q4, selling over 540,000 shares. Despite this, other institutional i...